Cingulate Inc. Warrants

Cingulate Inc. is a biopharmaceutical company that develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. Its lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for ADHD in children, adolescents, and adults. The company also develops CTx-2103 (buspirone) for anxiety, which is in a formulation stage, and plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Founded in 2012, Cingulate Inc. is headquartered in Kansas City, Kansas.